Clinical Trial Update: Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension [Phase 3]

View source ↗

Summary

Phase 3 trial investigating a bronchodilator for exertional dyspnea in pulmonary arterial hypertension was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: WITHDRAWN